Actively Recruiting
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Led by Radboud University Medical Center · Updated on 2023-01-18
150
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
Sponsors
R
Radboud University Medical Center
Lead Sponsor
H
Haukeland University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
CONDITIONS
Official Title
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of advanced stage (FIGO stage III or IV) or recurrent endometrial cancer
- Any histologic type of endometrial carcinoma
- Planned treatment with any type of hormonal therapy
- Biopsy taken within 120 days before starting hormonal therapy with no treatment between biopsy and therapy start
You will not qualify if you...
- Hormonal therapy started as adjuvant treatment after complete removal of endometrial cancer
- Use of hormonal therapy simultaneously for other reasons
- Diagnosis of endometrial sarcoma or endometrial stroma cell sarcoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Radboudumc
Nijmegen, Netherlands, 6525GA
Actively Recruiting
Research Team
M
Maartje Luijten, MD
CONTACT
H
Hanny Pijnenborg, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here